
![]() |
|||||||||||||
WJPR Citation Report
|
| All | Since 2021 | |
| Citation | 9186 | 4781 |
| h-index | 32 | 25 |
| i10-index | 256 | 108 |
A REVIEW ON NANOPARTICLE THERAPEUTICS IN FSHD: CURRENT RESEARCH AND FUTURE PERSPECTIVES
B. Indravathi, Prasanna Kumar Desu, B. Srinidhi, K. Harshitha*
Abstract Facioscapulohumeral muscular dystrophy (FSHD) is a genetic neuromuscular disease demonstrated by developing, asymmetric muscularimpairmentinduced by abnormal expression of the DUX4 (double homeobox 4) gene regulatory protein. There are presently no disease-altering therapiesprovided, and treatment accessibleendureregulated to assistive and indicativeapproachesthoughdevelopments in awareness of its molecular basis. Attempts have been meant to create treatmentmethods addressing DUX4 suppressing, genomicmodifying, and subsequent pathological mechanismschanging to consider its pendingclinical requirements. Clinical implementation is yethindered by the scarcity of efficient, organ-specific delivery to skeletal muscle. Nanotechnology-based vectors are potential for addressing these barriers, as they enhance tissue identifying while limiting off-target allocation and therapeutic drug content. In this review, we examine the existingscenario of FSHD treatments and emphasises how preclinical statistics on nanotherapeutics in Duchenne muscular dystrophy and variable muscular dystrophies illustrate the feasibility of nanoparticle-facilitatedtactics for muscle-targeted delivery and upgradeddrug availability in circulation, developingthese advancing inventions in FSHD therapeutics. We also manage challenges with nanoparticle-based methods for clinicalpractice, involvingdeficits in pro-longed safety, flexibility, and capability. By incorporatingperceptions from the molecular level genetics of FSHD and developments in nanomedicine in other muscular dystrophies, this review seeks to ensure aextensive interpretation on the prospects of nanotherapeutics and to overview future strategies for their clinical application in FSHD. Keywords: Facioscapulohumeral Muscular Dystrophy (FSHD), DUX4 Gene, Nanotechnology, Nanoparticles, Targeted Drug Delivery, Gene Therapy, Nanotherapeutics, Skeletal Muscle, Muscle Dystrophy, Therapeutic Approaches. [Full Text Article] [Download Certificate] |
